Skip to content

Effects of Burst Spinal Cord Stimulation Versus Paravertebral Block on Thoracic Subacute Herpetic Neuralgia: A Retrospective Study Based on Propensity Score Matching

Effects of Burst Spinal Cord Stimulation Versus Paravertebral Block on Thoracic Subacute Herpetic Neuralgia: A Retrospective Study Based on Propensity Score Matching

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116032
Enrollment
Unknown
Registered
2026-01-04
Start date
2026-01-04
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic Subacute Herpetic Neuralgia

Interventions

Observation group of subacute herpes zoster neuralgia in the thoracic segment:None

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age: 18 to 80 years old; 2. body mass index (BMI) : 18.5-30 kg/m ²; 3. American Society of Anesthesiologists (ASA) grade I to III; 4. It conforms to the definition of SHN in the "Expert Consensus on Diagnosis and Treatment of Herpes Zoster in China (2022 Edition)", with a disease course of 1 to 3 months; 5. The herpes zoster nerves distributed along the T1 to T12 segments are involved; 6. After regular oral administration of standard therapeutic drugs, the VAS score remains at or above 4 points, or adverse reactions of intolerance to the drugs occur; 7. No invasive interventional treatment was performed for SHN before the operation. 8. After admission, short-term Burst spinal cord electrical stimulation (burst-scs) was used for more than 7 days or ultrasound-guided thoracic paravertebral block (TPVB) was performed continuously for more than 7 times.

Exclusion criteria

Exclusion criteria: 1. Severe liver, kidney and heart dysfunction; 2. Patients with chronic pain; 3. Long-term oral analgesics; 4. Combined with lesions of the central nervous system or peripheral nervous system; 5. Those with severe scoliosis, spinal trauma, or surgeries on the cervical, thoracic or lumbar vertebrae; 6. Patients with mental disorders or severe psychological disorders; 7. Patients with chronic insomnia; 8. Pregnant or lactating women; 9. Those who already have electronic implants such as pacemakers in their bodies; 10. Incomplete data and information; 11. Those who combine multiple interventional treatment methods.

Design outcomes

Primary

MeasureTime frame
Visual Analog Scale;

Secondary

MeasureTime frame
Efficacy assessment;Incidence of PHN;Incidence of breakthrough pain;Mean number of breakthrough pain episodes per day;Incidence of touch-evoked pain;Severity of touch-evoked pain;Pittsburgh sleep quality index;Dosage of pregabalin;Oral morphine equivalent;

Countries

China

Contacts

Public ContactXiaokai Zhou

The First Affiliated Hospital of Nanjing Medical University

orthoxiaokaizhou@163.com+86 137 7052 7630

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026